Drug Description in Trials / DrugBank / KEGG DRUG
Search results
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 |
|---|---|---|---|---|---|---|
| 1 | All patients in the study will be treated with ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 2 | Continued Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 3 | OCR | - | - | - | - | 1件: 13 13 |
| 4 | OCRELIZUMAB | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 3件: 13 13, 46, 49 |
| 5 | Ocrelizumab (CinnaGen, Iran) | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 6 | Ocrelizumab (Roche, Switzerland) | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 7 | Ocrelizumab / rhuMAb 2H7 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
| 8 | Ocrelizumab 300 mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 9 | Ocrelizumab 300mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 10 | Ocrelizumab 300mg /10ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 11 | Ocrelizumab 300mg/10 ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 12 | Ocrelizumab 300mg/10ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 13 | Ocrelizumab 500mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
| 14 | Ocrelizumab 600 mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 15 | Ocrelizumab at home | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 16 | Ocrelizumab Dose 1 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 17 | Ocrelizumab Dose 2 and Dose 3 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 18 | Ocrelizumab IV | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 19 | Ocrelizumab SC | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 20 | Ocrelizumabu 200mg | - | - | - | - | 1件: 46 46 |
| 21 | Ocrelizumabu 50mg | - | - | - | - | 1件: 46 46 |
| 22 | OCREVUS | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 23 | Ocrevus 300 mg, solution à diluer pour perfusion | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 24 | Ocrrelizumab 300 mg | - | - | - | - | 1件: 13 13 |
| 25 | Other: Observation of Ocrelizumab as Treatment in RRMS Patients | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 26 | Other: Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
| 27 | Ovine Corticotropin-Releasing Hormone (oCRH) | 2件: Corticorelin Corticorelin,Corticotropin | 2件: D00146
D00146
,D03905 | 3件: CRHR1 CRHR1,CRHR2, MC2R 💬 | 6件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 |
| 28 | Short-course Ocrelizumab | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
(Name: Ocrelizumab) | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |